Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) has issued an update.
Tonix Pharma disclosed that certain financial or operational information referenced in one section of its regulatory filing has been formally incorporated by reference into another section. This procedural disclosure indicates an administrative alignment of previously reported data rather than a new operational development, suggesting no immediate change to the company’s business activities or outlook for stakeholders.
The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held down primarily by very weak profitability and ongoing heavy cash burn, with additional pressure from bearish technicals. Positive recent corporate updates and a stronger, low-debt balance sheet provide some offset, but do not yet overcome the fundamental cash-flow and operating-loss profile.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharma is a biopharmaceutical company focused on developing and commercializing therapies in the pharmaceutical and life sciences sector. The company typically targets unmet medical needs with a pipeline of product candidates designed for various central nervous system and other disorders, positioning it within the innovative drug development segment of the healthcare industry.
Average Trading Volume: 393,254
Technical Sentiment Signal: Sell
Current Market Cap: $183.7M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.